The potential use of clinically approved beta-lactams for Buruli ulcer (BU) treatment was 36 investigated with representative classes analyzed in vitro for activity against 37
AUTHOR SUMMARY 48
Buruli ulcer (BU) is a chronic debilitating disease of the skin and soft tissue, mainly 49 affecting children and young adults in tropical regions. Before 2004, the only treatment 50 option was surgery; a major breakthrough was the discovery that BU could be cured in 51 most cases with a standard treatment that involved 8 weeks of combination therapy with 52 rifampicin and streptomycin. However, the use of streptomycin is often associated with 53 severe side effects such as ototoxicity, nephrotoxicity, or hepatotoxicity. More recently, 54 a clinical trial demonstrated equipotency of replacing the injectable streptomycin by the 55 clarithromycin, which is orally available and with fewer side effects. Thus, BU treatment 56 is now moving toward a full orally available treatment of clarithromycin-rifampicin. 57 However, recent studies have reported the emergence of strains resistant to rifampicin 58 and streptomycin. Since no alternatives to rifampin are available, it is considered the 59 cornerstone drug for BU therapy. Strains resistant to clarithromycin could also 60 eventually emerge. Thus, there is a need to find new therapies for BU. 61
In this work, we describe for the first time the potential inclusion of beta-lactams in BU 62 therapy. More specifically, we propose the use of amoxicillin/clavulanate since it is oral, 63
suitable for the treatment of children, and readily available with a long track record of 64 clinical pedigree. Its inclusion in a triple oral therapy complementing current 65 combinatorial rifampicin-clarithromycin treatment has the potential to counteract 66 resistance development and to reduce length of treatment and time to cure. 67
INTRODUCTION 68
Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a chronic debilitating 69 mycobacterial disease of the skin and soft tissue. Although mortality is low, permanent 70 disfigurement and disability is high, mainly affecting children and young adults. BU is 71
found primarily in tropical regions of Africa, South America and the Western Pacific; 72 however, it is also becoming a public health concern in some regions of Australia, 73 especially in the temperate South-Eastern state of Victoria. This worsening epidemic 74 with increased number of cases in the last few years had an estimated cost to Victoria 75 of $2,548,000 in 2016 and ca. $14,000 per patient 1 . 76
Before 2004, when the World Health Organization (WHO) published provisional 77 guidance for the management of BU disease 2 , antibiotics were viewed as relatively 78
ineffective and surgery remained the mainstay of treatment for BU 3 . Several attempts 79 had been made to develop an effective antimicrobial BU therapy but without desirable 80 outcomes 4, 5 . In the late 1990s and early 2000s, however, in vitro studies demonstrated 81
anti-BU activity of some antibiotics used for the treatment of tuberculosis (TB) and other 82 non-tuberculous mycobacteria, including macrolides 6 , fluoroquinolones, rifampicin 7 and 83 aminoglycosides 8 . This knowledge led to further in vivo studies demonstrating the 84 potential for combining two drugs to provide optimal treatment outcomes 9-13 . Soon after, 85 clinical evidence demonstrated the effectiveness of a combination of rifampicin plus 86 streptomycin when it was administered for at least 4 weeks 14 and that routine 87 implementation of such a therapy was possible in the field 15, 16 . This game changer 88 therapy involved 8 weeks of daily painful deep intramuscular injections of streptomycin; 89 however, the use of streptomycin is often associated to adverse events such as oto-, 90 nephron-and hepatotoxicy and is restricted in the treatment of pregnant women and 91 young infants. In addition, the lack of an efficacious oral treatment remained one of the 92 main obstacles to decentralizing care at local level in rural areas. Together, these 93 limitations motivated the scientific community to evaluate alternative oral treatments that 94 did not include streptomycin. Clinical studies demonstrated that fluoroquinolones 17 or 95 clarithromycin [18] [19] [20] , could also be used in combination with rifampicin. Since 96 clarithromycin is orally available and with fewer side effects compared to the injectable 97 streptomycin, on March 24 th , 2017, WHO recommended moving toward adoption of a 98 full oral treatment of 8 week daily combination therapy of rifampicin-clarithromycin in its 99 "Report from the Biennial Meeting of the Buruli ulcer Technical Advisory Group" 21 100
Although antimicrobial therapy is major step toward the management of this infectious 101 disease, eventual failure due to the development of resistance is anticipated. M. 102
ulcerans strains resistant to rifampicin have already been isolated after experimental 103 chemotherapy in mice 22 and a recent report described the emergence of M. ulcerans 104 strains resistant to rifampicin and streptomycin in the clinic 23 . WHO currently 105 recommends only four drugs for the treatment of BU: rifampicin, streptomycin, 106 clarithromycin and moxifloxacin 2 . Rifampicin is the essential partner in combinatorial 107 5 therapy since its sterilization properties prevents relapse of the disease 13 , making it the 108 cornerstone drug for BU therapy. As such, no alternatives for rifampicin are currently 109 available and new oral therapeutic options readily available in the clinic should be 110 explored that are suitable for children and pregnant women. 111
In this study, we are translating knowledge and concepts of drug repurposing and 112 synergies generated in TB R&D programs to assess the potential inclusion of beta-113 lactams to complement current anti-BU therapy. We proposed the combination of 114 amoxicillin/clavulanate as a new anti-BU treatment in combination with current oral BU 115 therapy, rifampicin and clarithromycin, with the potential of treatment shortening and 116 readily implementation in the field. 117 
MATERIAL AND METHODS

RESULTS 162
Rifampicin has strong synergistic interactions with beta-lactams but not with 163 current anti-BU drugs. Clinically approved beta-lactams representing different sub-164 families, i.e. meropenem (carbapenems), cephradine and cefdinir (cephems), 165 faropenem (penems) and amoxicillin (penicillins) were assayed in vitro in a 166 checkerboard format to assess their synergistic interactions with rifampicin in the 167 absence and presence of clavulanate, a beta-lactamase inhibitor, against the M. 168
ulcerans ATCC strain. A pattern of strong synergistic interaction was observed between 169 rifampicin and all the beta-lactam tested (Figure 1) ; however, no interaction was 170 observed when the same assay was conducted using combinations of rifampicin and 171 the currently WHO recommended anti-BU drugs, i.e. streptomycin, clarithromycin and 172 moxifloxacin ( Figure S1 ). Dose-response curves indicated that the activity of rifampicin 173 (reflected in MIC reduction) was increased on average 16-32-fold (up to 128-fold in 174 some cases) and, vice versa, the activity of the beta-lactams was strongly enhanced by 175 rifampicin. In the case of amoxicillin, its activity was further increased 512-fold in 176 combination with clavulanate ( Figure S2 and Table S1 ). 177
Beta-lactams not only had synergistic interactions with rifampicin but also with 178 clarithromycin, the second drug recommended as first-line anti-BU therapy. These 179 results prompted us to test the inhibitory effect of double clarithromycin-beta lactam, 180
and triple rifampicin-clarithromycin-beta-lactam combinations (Figure 2) . Our results 181 indicated that, when in double or triple combinations, much lower sub-inhibitory 182 concentrations were equally potent at inhibiting M. ulcerans growth than the additive 183 effects of the compounds alone. MIC values were also lower than in other pairwise 184 combinations. For example, the MIC of amoxicillin was greater than 32 µg/mL; however, 185 its synergistic MIC (MIC syn ) was reduced to 1 µg/mL in the presence of rifampicin, to 186 0.25 µg/mL when clavulanate was also added, or to 0.062 µg/mL when both clavulanate 187 and clarithromycin were included together with rifampicin, i.e., an MIC reduction of ca. 188 500-fold for amoxicillin when in the quadruple combination. Similar results were 189 obtained for combinations of meropenem or faropenem and rifampicin, with MIC 190 reductions as high as 80-fold when tested within triple combinations. In these assays, 191
clarithromycin was added at a fixed concentration of 1/8 its MIC value alone, being its 192 presence critical to achieve the multiplicative effect observe in the quadruple 193 combinations. 194
Amoxicillin/clavulanate is highly active against M. ulcerans clinical isolates in 195
combination with rifampicin and clarithromycin. Our initial discoveries described 196 above were performed using the reference M. ulcerans ATCC strain. In order to validate 197 the pattern of synergistic interactions between rifampicin, clarithromycin and beta-198 lactams and to gauge the potential of introducing a beta-lactam in the treatment of BU, 199
we expanded our analysis to a collection of M. ulcerans clinical isolates from different 200 geographical locations and focused our synergy interaction studies on the amoxicillin 201 /clavulanate combination. When in the quadruple combinations, the activities of all three 202 drugs (clavulanate was added at a fixed 5 µg/mL concentration, more than 20-fold less 203 its MIC) were strongly enhanced; depending on the strain tested, these interactions 204 could range from ca. 5 to 600-fold (rifampicin), ca. 4 to 2,000-fold (amoxicillin) and ca. 205 20 to 80-fold (clarithromycin) ( Table 1) . Every possible pair-wise and triple combination 206 was also evaluated showing strong synergism between amoxicillin and both rifampicin 207 and clarithromycin, but not between rifampicin and clarithromycin, similar to previously 208 described for the ATCC strain. Clavulanate enhanced the activity of amoxicillin (as 209 expected) but had no effect over clarithromycin and only minor enhancements (in some 210 cases) over rifampicin (Table S3 ). 211
Amoxicillin is inactivated by beta-lactamases enzymes, limiting its clinical use. In fact, 212
dose-response studies demonstrated that amoxicillin alone was not active (MIC > 16 213 µg/mL); however, a strong shift in the dose-response curve was observed by adding 214 clavulanate and this shift was further enhanced when clarithromycin and rifampicin were 215 also present in the combination at sub-MIC concentrations (Figure 3) , thus confirming 216 our MIC/synergy data and the potential of amoxicillin/clavulanate as a new anti-BU 217 therapy, both alone and in combo with rifampicin, clarithromycin or both. 218
DISCUSSION 219
In this study, we have in vitro characterized the antimicrobial interactions of rifampicin 220 with anti-BU drugs and beta-lactams and found that, while there was no synergy 221 between rifampicin and current anti-BU drugs, it had strong synergistic interactions with 222 beta-lactams. What is more, beta-lactams also displayed synergism with clarithromycin, 223 the other first line drug in BU therapy. Our studies confirmed previous data showing lack 224 of in vitro interaction between rifampicin and clarithromycin 26 , thus reinforcing synergy 225
data observed with beta-lactams. 226
Working with M. ulcerans is challenging due to its slow generation time (ca. 48 hours), 227 even slower than M. tuberculosis. Current methodologies to perform susceptibility 228 testing against clinical isolates are often time consuming and cumbersome (use of agar 229
proportion methods), thus, requiring several weeks to generate results 6, 8, 23 . 230
Improvements have been introduced using luminescent reporter strains 27 ; however, this 231
technology is limited to specific engineered strains and cannot be widespread applied to 232 clinical isolates. Here, we were able to perform synergy studies, obtaining results in just 233 seven days, in a medium-throughput manner against a panel of clinical isolates by using 234 an experimental design previously described for TB research 25 . Briefly, a synthetic 7H9 235 mycobacteria broth micro-dilution assay (96-and 384-well plates) was employed 236
coupled to a modification of the MTT method 28 , where the MTT solution was added 237 together with 20% of Tween 80 to solubilize the formazan precipitate in a one-step 238 reaction. We found that MTT provided a more robust signal and wider dynamic range 239 than resazurin-based micro-dilutions assays 29, 30 . This methodology provides a cost 240 and time effective assay to implement in the clinical practice in drug resistance 241 surveillance campaigns. 242 Before 2004, surgery was the only option available for the treatment of Buruli ulcer. 243
Over the last decade, therapy has experience a tremendous improvement with the 244 introduction of chemotherapy; however, there is only a limited number of drugs 245 recommended by WHO for BU therapy, namely rifampicin, streptomycin, clarithromycin 246 and moxifloxacin 2 . Current WHO recommended therapy is a fully oral eight weeks daily 247 regime with a combination of rifampicin and clarithromycin 20 . Although effective and 248 mostly well tolerated, combination treatment of rifampicin plus streptomycin or 249 clarithromycin are associated with undesirable side effects that might include mild 250 (anorexia, nausea, abdominal pains and altered taste) or severe (deafness, skin rashes, 251 jaundice, shock, purpura or acute renal failure) symptoms 2 . In such a scenario, where 252 administration of any of these drugs needs to be interrupted, therapeutic options remain 253 limited to the use of moxifloxacin, an antibiotic contraindicated during pregnancy and 254 within the pediatric population. A similar situation would occur in the eventual 255 development of resistance to any of these drugs, especially rifampicin. Since they are 256 administered in pairwise combinations, this would effectively imply monotherapy, further 257 promoting the emergence of resistance. This is similar to already seen in another 258 11 mycobacterial disease, leprosy, for which this threat was largely ignored and just 259 recently WHO issued guidelines including procedures for the detection of drug 260 resistance 31 . Thus, an alternative drug regimen would be required to treat resistant M. 261
ulcerans strains 23 . 262
The WHO recommended regimen allowed, however, cure of small lesions (<5 cm in 263 diameter) without surgery 15, 18 . Controversy remained regarding the best approach for 264 large lesions (>10 cm) whether to combine prolonged chemotherapy (up to 12 weeks) 265
with surgery 32 or to delay this intervention 33 better than daily rifampin 35 . Moreover, such a BU regimen would still rely on a two-drug 281 combination therapy, with all the shortcomings above described. 282
The history of TB chemotherapy teaches us that combination therapy is critical for 283 optimal cure outcome. The first anti-TB drug, streptomycin, discovered in 1944, was 284 immediately used in monotherapy for treatment of TB patients. After an initial 285 improvement over the first months, health deterioration ensued due the development of 286 resistant M. tuberculosis strains, rendering streptomycin ineffective. To overcome these 287 limitations the first combination therapy for the treatment of a disease was developed 288 using para-aminosalicylic acid together with streptomycin. However, this therapy still 289 required 18 months of treatment. It was only after the discovery of rifampicin in 1965 290 and the subsequent introduction of this drug in the combination therapy that treatment 291 could be reduced to 9 months. Today, the WHO recommended TB treatment include a 292 combination of four drugs for 2 months (rifampicin, isoniazid, ethambutol, and 293 pyrazinamide) plus a continuation phase of 4 months with just rifampicin and isoniazid 36 . 294
Translating this knowledge into BU therapy, it remains clear that more drugs need to be 295
added to the current rifampicin-clarithromycin combination in order to improve and 296
shorten the duration of treatment. 297
Rifampin is the cornerstone drug for TB (and BU) therapy. There is a direct relation 298 between dose increase and therapy efficacy 37 due to its bactericidal and sterilizing 299 activity in a dose-dependent manner 38 . However, the current WHO recommended dose 300 of 10 mg/kg (current 600 mg daily) is not used routinely at its optimal clinical dose 39 . In 301 fact, it was introduced in 1971 based on pharmacokinetic, toxicity, and cost 302
considerations but some recent studies suggest that rifampicin dose could be safely 303 increased to 35 mg/kg daily 37 . Follow up efficacy studies revealed that only doses of 35 304 mg/kg 40 , but not lower 41 , had a bacteriological effect on time to culture conversion, 305
suggesting that synergistic partners could serve to improve rifampicin efficacy without 306 compromising tolerability and toxicity. 307
Drug development for neglected diseases such as BU, mainly affecting developing 308 countries, is especially complicated due to lack of interest from the main scientific and 309 industrial communities and, as a consequence, lack of investment. To overcome these 310 limitations and speed up the discovery and development process, we applied 311 knowledge gathered in TB R&D programs using a drug repurposing approach 24, 25, 42, 43 . 312
In these programs, we aimed to improve the activity of rifampicin within a synergistic 313
combination with the hypothesis that if rifampicin efficacy could be increased, TB 314 therapy could be shortened, while reducing toxicity. In the course of this program we 315
(and others 44 ) identify that beta-lactams strongly increased the bactericidal and 316 sterilizing properties of rifampicin 25 . 317
Beta-lactams are one of the largest groups of antibiotics available today with an 318 exceptional record of clinical safety in humans. With over 34 FDA-approved beta-319 lactams, they are the most widely used antibiotics in history constituting ~50% of all 320 antibiotic prescriptions worldwide 45 . Used for decades to treat diseases caused by 321 bacteria, they had been traditionally considered to be ineffective for the treatment of 322 mycobacterial infections (mainly TB) due to the presence of a beta-lactamase (BlaC) 323 able to degrade these antibiotics, and the hydrophobic nature of the mycobacterial cell 324 envelope that limits beta-lactam access to their cellular targets 46 But, what could be the benefit of adding amoxicillin/clavulanate to the current anti-BU 398 therapy? Besides being able to treat secondary infections associated with BU lesions, it 399 has been proposed that the median time to healing is related to the bacterial load in the 400 lesions at the beginning of therapy and the presence of persister bacteria 62 ; in fact, 401
healing of up to two thirds of patients occurs within 25 weeks from the start of treatment 402 but for some patients this can take up to a year. One of the reasons for this slow healing 403 could be due to a high initial bacterial load. In fact, active infection late into the 404 recommended 8-week course of antibiotic therapy could be found in slowly healing 405 lesions 32, 63 . Amoxicillin/clavulanate could have the potential to address these issues 406 since it is extremely effective at targeting extracellular bacteria with a rapid bactericidal 407 activity and extensive histopathologic studies demonstrate that M. ulcerans is 408 essentially confined in extracellular areas of necrosis in skin 6 . Amoxicillin/clavulanate 409 could have an important role at rapidly reducing the initial bacterial load. Fold-Reduction, MIC/MICsyn FICI, Fractional Inhibitory Concentration Index. Synergy: FICI ≤0.5; No interaction, FICI = 0.5-4; Antagonism, FICI >4 FICI is calculated for pair-wise, triple or quadruple combinations depending on the number of drugs in the combo. RIF, rifampicin; CLA, clarithromycin; STR, streptomycin; MOX, moxifloxacin; AMK, amikacin; CPD, cephradine; CDN, cefdinir; MER, meropenem; FAR, faropenem; AMX, amoxicillin; CLV, clavulanate Clarithromycin activitiy was not increased in the presence of clavulanate (not shown). When in quadruple combinations, clarithromycin was tested at 1/8xMIC concentrations (MIC = 0.5 µg/mL) Clavulanate was tested at a fixed 5 µg/mL concentration. When MIC values are not reached (i.e. >32 µg/mL) the next two-fold dilution higher (i.e. 64 µg/mL) is used for fold-reduction calculations Synergism  ITM 070290  RIF  AMX  ND  ND  ND  ND  ND  ND  RIF  CLV  ND  ND  ND  ND  ND  ND  RIF  CLA  ND  ND  ND  ND  ND  ND  AMX  CLV  ND  ND  ND  ND  ND  ND  AMX  CLA  ND  ND  ND  ND  ND  ND  CLV  CLA  ND  ND  ND  ND  ND  ND  RIF  AMX  CLV  ND  ND  ND  ND  ND  ND  ND  ND  RIF  CLV 
